Big Al’s Reputation1 Nov 2020 19:45
Big Al’s Reputation
Over the last few weeks, there has been a lot of mud thrown at Avacta board and especially Big Al.
His House move, selling of shares,No news but this has all been by greedy Aim investors, with NO patience all wanting to bag x 10 as quick as possible,so they can move on to their next Aim share and help pay for their losses they have accrued through being greedy and trying to bet on shares they have not put no research into.
I’ve done my research,God if you can’t find time to do research this year when will you find time.
Many have lost money on Avacta in the past since their IPO. Even just 5 years ago Avacta share price was hovering around today’s price then it took a bit of a dive to all time low this year this caused again by impatient investors.
Major pharma companies take up to 15 to 20 years to get a drug to market and costs a fortune,that’s why the drugs cost so much when they are on patent.
Look back at all the RNS and you can follow what Big Al is trying to achieve but it takes time.
2015
Dr Mike Owen appointed as Non-executive Director. Previously SVP and global Head of Biopharmaceuticals Research at GlaxoSmithKline.
Dr Owen was Senior Vice President and global Head of Research of the Biopharmaceuticals R&D Unit at GlaxoSmithKline and was responsible for initiating and rapidly growing GSK's robust pre-clinical and clinical therapeutic antibody pipeline during the last decade through in-house development as well as through acquisitions such as Domantis. He left GSK in 2010 to establish Kymab which is developing biotherapeutics using its novel transgenic mouse platform. Dr Owen is an immunologist by training who had a highly successful scientific career at Imperial Cancer Research during which he was elected a member of the European Molecular Biology Organisation and a fellow of the Academy of Medical Sciences.
Neil Bell
Chief Development Officer
Neil is responsible for late stage pre-clinical and early clinical development of Avacta’s pipeline of pre|CISIONTM pro-drugs and Affimer® immunotherapies.
Neil has over 30 years’ experience in the drug development industry, having held senior positions in global pharmaceutical companies and innovative biotechs. The early part of his career was spent in clinical development at Eisai and Pfizer before becoming Therapeutic Area Head for Gastroenterology and Neurology at Ipsen. In each of these roles he led numerous Phase I to III clinical studies, gaining significant experience across all facets of drug development; from strategy to pre-clinical development, manufacturing and regulatory, to clinical study design and implementation.
In his role as Head of Global Clinical Operations for Teva Pharmaceuticals, Neil led an international team responsible for the delivery of clinical programmes in neurology, autoimmune and oncology therapeutic areas.
To me you don’t have someone with Dr Owen’s skills and stay in a small company for 5 years. He has seen the
Sign In
Follow the stocks
